New insider activity at Seer ( (SEER) ) has taken place on May 21, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Seer’s President and CFO, David R. Horn, has sold 7,303 shares of Seer stock in a recent transaction, with the total sale valued at $12,342.
Recent Updates on SEER stock
Seer shares have been volatile as investors digest weak Q1 results alongside rising strategic tension and IP moves. The stock is reacting to a sharp revenue and margin decline, continued cash burn, and cautious guidance, partially balanced by strong scientific validation, large biobank collaborations, and a new commercial chief aimed at improving execution.
Analyst sentiment and targets are being reassessed mainly because of the disconnect between Seer’s sizable cash balance and ongoing losses, softer funding and tougher competition, and uncertainty over how fast biobank and proteomics demand will convert to revenue. The board’s rejection of a takeover offer and Seer’s patent suit against an alleged imitator also feed into views on governance risk, legal costs, and the long-term value of its proteomics platform.
Spark’s Take on SEER Stock
According to Spark, TipRanks’ AI Analyst, SEER is a Neutral.
The score is held down primarily by weak financial performance (small/declining revenue, large losses, and ongoing cash burn) and bearish technical positioning (trading below major moving averages with weak momentum). The earnings call adds partial support via reaffirmed guidance, cost discipline, strong cash reserves and buybacks, but near-term revenue/margin pressures and negative free cash flow keep overall risk elevated.
To see Spark’s full report on SEER stock, click here.
More about Seer
YTD Price Performance: -8.20%
Average Trading Volume: 381,205
Technical Sentiment Signal: Strong Sell
Current Market Cap: $92.37M